Memory chipmaker Micron Technology Inc. (NASDAQ: MU) on Wednesday reported stronger-than-expected earnings for the first quarter of fiscal 2026. Revenue increased 57%
Micron Q1 2026 earnings beat estimates; revenue surges 57%
Categories
pharmaceuticals
Pfizer affirms FY25 earnings guidance, provides full-year 2026 outlook
Pfizer Inc. (NYSE: PFE) has reaffirmed its earnings outlook for fiscal 2025 and revised revenue guidance. The pharma giant also initiated guidance
Unicycive is all-in on kidney care, focusing on underserved areas: CEO
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a biotech firm engaged in the development of novel treatment options for patients with renal diseases.
Earnings Summary: CooperCompanies reports higher Q4 revenue, adj. profit
CooperCompanies (NYSE: COO) has reported an increase in revenues and adjusted earnings for the fourth quarter of fiscal 2025. The medical device
Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO
CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on hematologic malignancies
Viatris (VTRS) posts Q3 2025 results and updates 2025 guidance
Pharmaceuticals company Viatris Inc. (NASDAQ: VTRS) on Thursday reported financial results for the third quarter of fiscal 2025, and updated its outlook
Earnings Summary: Humana Q3 2025 profit drops despite higher revenues
Humana Inc. (NYSE: HUM), a leading health and well-being company, on Wednesday reported a decline in adjusted earnings for the third quarter
Key takeaways from Pfizer’s (PFE) Q3 2025 earnings report
Shares of Pfizer Inc. (NYSE: PFE) stayed green during midday trade on Tuesday following the company’s announcement of its third quarter 2025
PFE Earnings: All you need to know about Pfizer’s Q3 2025 earnings results
Pfizer Inc. (NYSE: PFE) reported its third quarter 2025 earnings results today. Revenues were $16.7 billion, down 6% on a reported basis
ABBV Earnings: A snapshot of AbbVie’s Q3 2025 report
Pharmaceuticals company AbbVie, Inc. (NYSE: ABBV) on Friday reported a decline in earnings for the third quarter of fiscal 2025, despite an
BIIB Earnings: A snapshot of Biogen’s Q3 2025 results
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported an increase in adjusted profit for the third quarter of 2025 when its revenues remained
Earnings Summary: Cardinal Health Q1 2026 revenue jumps 22%; raises guidance
Pharmaceuticals distributor Cardinal Health (NYSE: CAH) reported a sharp increase in revenue and adjusted earnings for the first quarter of fiscal 2026.
Bristol Myers Squibb (BMY) Earnings: 3Q25 Key Numbers
Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2025 earnings results today. Revenues increased 3% year-over-year to $12.2 billion. GAAP net
Eli Lilly (LLY) Earnings: 3Q25 Key Numbers
Eli Lilly and Company (NYSE: LLY) reported its third quarter 2025 earnings results today. Worldwide revenue was $17.60 billion, up 54% from
Key highlights from Merck’s (MRK) Q3 2025 earnings results
Merck & Co., Inc. (NYSE: MRK) reported its third quarter 2025 earnings results today. Total worldwide sales of $17.3 billion were up
UnitedHealth Group’s Q3 2025 earnings fall despite double-digit revenue growth
Healthcare behemoth UnitedHealth Group (NYSE: UNH) announced results for the third quarter of fiscal 2025, reporting an increase in revenues and a
Abbott Laboratories Q3 adj. earnings rise on higher sales; meet Street view
Abbott Laboratories (NYSE: ABT) reported higher sales and adjusted earnings for the third quarter of fiscal 2025. The healthcare company also reaffirmed
Kairos Pharma’s goal is to intervene early in resistance and re-sensitize cancer cells to therapy: CEO
Kairos Pharma, Ltd. (NYSE: KAPA) is a biopharma company developing a pipeline of targeted therapies for cancer patients with high unmet medical
JNJ Earnings: Key quarterly highlights from Johnson & Johnson’s Q3 2025 financial results
Johnson & Johnson (NYSE: JNJ) reported its third quarter 2025 earnings results today. Reported sales increased 6.8% year-over-year to $24 billion. Operational
IPO News: MapLight Therapeutics targets $704 mln valuation in Nasdaq debut
In recent months, Wall Street has seen a surge of healthcare firms seeking to go public, as IPO activity continues to regain
Innovation pipeline, portfolio in focus ahead of Johnson & Johnson’s Q3 earnings
For Johnson & Johnson (NYSE: JNJ), 2025 has been a strong year, marked by an impressive financial performance that drove the stock